HK1213148A1 - 離子交換膜的從細胞結合劑細胞毒性劑綴合物中去除雜質的用途 - Google Patents

離子交換膜的從細胞結合劑細胞毒性劑綴合物中去除雜質的用途 Download PDF

Info

Publication number
HK1213148A1
HK1213148A1 HK16101358.6A HK16101358A HK1213148A1 HK 1213148 A1 HK1213148 A1 HK 1213148A1 HK 16101358 A HK16101358 A HK 16101358A HK 1213148 A1 HK1213148 A1 HK 1213148A1
Authority
HK
Hong Kong
Prior art keywords
ion exchange
exchange membrane
cytotoxic agent
remove impurities
cellbinding
Prior art date
Application number
HK16101358.6A
Other languages
English (en)
Chinese (zh)
Inventor
Xinfang LI
Wenjie CHENG
Original Assignee
Immunogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen, Inc. filed Critical Immunogen, Inc.
Publication of HK1213148A1 publication Critical patent/HK1213148A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
HK16101358.6A 2012-10-04 2013-10-04 離子交換膜的從細胞結合劑細胞毒性劑綴合物中去除雜質的用途 HK1213148A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261709871P 2012-10-04 2012-10-04
US61/709,871 2012-10-04
PCT/US2013/063503 WO2014055893A1 (en) 2012-10-04 2013-10-04 Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates

Publications (1)

Publication Number Publication Date
HK1213148A1 true HK1213148A1 (zh) 2016-06-30

Family

ID=50435480

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101358.6A HK1213148A1 (zh) 2012-10-04 2013-10-04 離子交換膜的從細胞結合劑細胞毒性劑綴合物中去除雜質的用途

Country Status (13)

Country Link
US (1) US20150307596A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2903450A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2015535215A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN105208876A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013326897A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2886996A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1213148A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL238111A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2015DN03203A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2015004258A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2015116883A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201502430QA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014055893A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007024536A2 (en) 2005-08-24 2007-03-01 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
RU2765240C2 (ru) 2009-06-03 2022-01-27 Иммьюноджен, Инк. Способы конъюгации
KR102272828B1 (ko) 2011-03-29 2021-07-05 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
SG11201502429YA (en) * 2012-10-04 2015-04-29 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
GB201616758D0 (en) * 2016-10-03 2016-11-16 Ge Healthcare Bio Sciences Ab Novel chromatography media
CN108549763B (zh) * 2018-04-09 2021-06-01 电子科技大学 一种用于离子推进器数值模拟的电荷交换碰撞mcc方法
CN118290514B (zh) * 2024-06-05 2025-04-04 东曜药业有限公司 基于阴离子膜的抗体偶联药物的纯化方法及抗体偶联药物
CN118290513B (zh) * 2024-06-05 2025-03-14 东曜药业有限公司 一种去除抗体偶联药物中游离小分子的阴离子柱层析方法及抗体偶联药物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050031627A1 (en) * 2002-01-03 2005-02-10 Mazzola Gregory J Methods for preparing immunoconjugates
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US20060182750A1 (en) * 2005-02-11 2006-08-17 Immunogen, Inc. Process for preparing stable drug conjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
WO2007024536A2 (en) * 2005-08-24 2007-03-01 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
RU2765240C2 (ru) * 2009-06-03 2022-01-27 Иммьюноджен, Инк. Способы конъюгации
KR102272828B1 (ko) * 2011-03-29 2021-07-05 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조

Also Published As

Publication number Publication date
IN2015DN03203A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-10-02
US20150307596A1 (en) 2015-10-29
CN105208876A (zh) 2015-12-30
SG11201502430QA (en) 2015-04-29
WO2014055893A1 (en) 2014-04-10
EP2903450A4 (en) 2016-05-11
JP2015535215A (ja) 2015-12-10
RU2015116883A (ru) 2016-11-27
MX2015004258A (es) 2015-09-25
EP2903450A1 (en) 2015-08-12
AU2013326897A1 (en) 2015-05-07
IL238111A0 (en) 2015-05-31
CA2886996A1 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
HK1213148A1 (zh) 離子交換膜的從細胞結合劑細胞毒性劑綴合物中去除雜質的用途
HK1213288A1 (zh) 使用pvdf膜純化細胞結合劑細胞毒性劑綴合物
NZ721952A (en) Delayed release compositions of linaclotide
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
HK1217215A1 (zh) 用於改变细胞表型的信号传感器多核苷酸
WO2009135646A3 (en) Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
HK1203513A1 (en) Methods of preparing substituted nucleotide analogs
WO2013057570A3 (en) Acrylic polymer formulations
HK1206028A1 (en) Phenicol antibacterials
WO2015168521A3 (en) P97-polynucleotide conjugates
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
HK1248069A1 (zh) 去乙酰氧基微管溶素h及其类似物
WO2014076712A3 (en) Lurasidone hydrochloride solid dispersion
WO2008140641A3 (en) Pure paliperidone and processes for preparing thereof
WO2012053009A3 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
WO2014180533A3 (de) Konjugate zum schutz vor nephrotoxischen wirkstoffen
WO2015042414A8 (en) Multicyclic compounds and methods of using same
WO2008137134A3 (en) Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
IL233055A (en) History of (1r, r4) 7 – oxo – 2 – azabicyclo [2.2.2] oct – 5 – ann
WO2015095659A3 (en) Indirubin solid dispersion composition
PH12014501367A1 (en) Processes for making magnolol and derivatives thereof
WO2011107967A3 (en) Improved polymer membranes, processes for production thereof and use thereof
WO2014009970A3 (en) Linagliptin solid dispersion
EP2364967A8 (en) Process for preparation of rasagiline and salts thereof
WO2014159501A3 (en) Processes for preparing tetrahydroisoquinolines